David A. Ramies

5.0k total citations · 2 hit papers
37 papers, 3.8k citations indexed

About

David A. Ramies is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, David A. Ramies has authored 37 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in David A. Ramies's work include Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Research Studies (8 papers). David A. Ramies is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Research Studies (8 papers). David A. Ramies collaborates with scholars based in United States, Canada and United Kingdom. David A. Ramies's co-authors include Roy S. Herbst, David H. Johnson, Bruce E. Johnson, Vincent A. Miller, Alan Sandler, Pam Klein, Hai T. Tran, Róbert Hermann, Mark G. Kris and Diane Prager and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

David A. Ramies

35 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

2005 1.2k citations Roy S. Herbst, Bruce E. Johnson et al. Journal of Clinical Oncology profile →
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

2005 1.2k citations David A. Eberhard, Bruce E. Johnson et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by David A. Ramies

Since Specialization

Citations

This map shows the geographic impact of David A. Ramies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Ramies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Ramies more than expected).

Fields of papers citing papers by David A. Ramies

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Ramies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Ramies. The network helps show where David A. Ramies may publish in the future.

Co-authorship network of co-authors of David A. Ramies

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Ramies. A scholar is included among the top collaborators of David A. Ramies based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Ramies. David A. Ramies is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	655O Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC) 2023 ·Annals of Oncology ·Byoung Chul Cho, Melissa L. Johnson, Jair Bar, Eric Schaefer, Kiyotaka Yoh, Alona Zer, (unknown), SH Lee, Víctor Moreno, Maria J. de Miguel, Yusuke Okuma, JH Kim, Chih‐Hsin Lee, Peter Ansell, (unknown), (unknown), Kevin J. Freise, David A. Ramies, Edwin E. Jeng, D. Ross Camidge	5
2	Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors 2022 ·Clinical Pharmacology in Drug Development ·Shringi Sharma, Xavier Pépin, Haran Burri, Lianqing Zheng, Nataliya Kuptsova‐Clarkson, Anouk de Jong, Ting Yu, Holly L. MacArthur, Michał Majewski, John C. Byrd, Richard R. Furman, Joseph A. Ware, James Mann, David A. Ramies, Veerendra Munugalavadla, (unknown), Helen Tomkinson	14
3	New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS) 2021 ·Blood ·Shringi Sharma, Xavier Pépin, Haran Burri, Lianqing Zheng, Nataliya Kuptsova‐Clarkson, Anouk de Jong, Ting Yu, Holly L. MacArthur, Michał Majewski, Joseph A. Ware, James Mann, David A. Ramies, Veerendra Munugalavadla, (unknown), Helen Tomkinson	8
4	Safety and Efficacy of Polatuzumab Vedotin + Obinutuzumab for Relapsed/Refractory NHL: A Phase 1b/2 Study 2021 ·SSRN Electronic Journal ·Tycel Phillips, Mark W. Brunvand, Andy I. Chen, James Essell, Annalisa Chiappella, Catherine Diefenbach, Ji Cheng, David A. Ramies, Jamie Hirata, Franck Morschhauser, Ian W. Flinn	0
5	Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes. 2020 ·Journal of Clinical Oncology ·Ehab Atallah, Samer K. Khaled, Brenda Cooper, Erica D. Warlick, David A. Ramies, Joanne Li, (unknown), Silvia Mappa, Michael Keng	3
6	Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small-cell Lung Carcinoma 2018 ·Clinical Lung Cancer ·Beth A. Hellerstedt, Nicholas J. Vogelzang, Harriet M. Kluger, Christopher A. Yasenchak, Dana T. Aftab, David A. Ramies, Michael S. Gordon, Primo Lara	18
7	Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS) 2018 ·Blood ·Michael Keng, Samer K. Khaled, Brenda Cooper, Erica D. Warlick, David A. Ramies, Silvia Mappa, Ehab Atallah	2
8	Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma. 2017 ·Journal of Clinical Oncology ·Joaquim Bellmunt, Sumanta K. Pal, Joel Picus, Manish Kohli, Yull Arriaga, Matthew I. Milowsky, Jocelyn Holash, David A. Ramies, Jesse McGreivy	10
9	Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib 2016 ·The Journal of Clinical Pharmacology ·Linh T. Nguyen, Jaymes Holland, David A. Ramies, Richard D. Mamelok, (unknown), (unknown), Thomas Marbury, Richard A. Preston, Douglas M. Heuman, Edith Gavis, Steven Lacy	46
10	Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT). 2012 ·Journal of Clinical Oncology ·Michael S. Gordon, Harriet M. Kluger, Geoffrey I. Shapiro, Razelle Kurzrock, Gerald M. Edelman, Thomas A. Samuel, (unknown), David A. Ramies, Alexander Laird, Frauke Schimmöller, Xiaodong Shen, Adil Daud	17
11	Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). 2012 ·Journal of Clinical Oncology ·Toni K. Choueiri, Sumanta K. Pal, David F. McDermott, David A. Ramies, Stephanie Morrissey, (unknown), Dale Miles, Jaymes Holland, Janice P. Dutcher	35
12	Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT). 2012 ·Journal of Clinical Oncology ·Beth A. Hellerstedt, Gerald M. Edelman, Nicholas J. Vogelzang, Harriet M. Kluger, Christopher A. Yasenchak, Xiaodong Shen, David A. Ramies, Michael S. Gordon, Primo N. Lara	24
13	Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). 2012 ·Journal of Clinical Oncology ·Toni K. Choueiri, Sumanta K. Pal, David F. McDermott, David A. Ramies, Stephanie Morrissey, (unknown), Dale Miles, Jaymes Holland, Janice P. Dutcher	13
14	Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). 2011 ·Journal of Clinical Oncology ·Ronald J. Buckanovich, Raanan Berger, Avishay Sella, Branimir I. Šikić, Xuemin Shen, David A. Ramies, David C. Smith, Ignace Vergote	36
15	Antitumor activity observed in a phase I drug–drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC). 2011 ·Journal of Clinical Oncology ·Toni K. Choueiri, Sumanta K. Pal, Maria E. Cabanillas, David A. Ramies, Lillian Tseng, Jaymes Holland, Shirley Morrissey, (unknown)	7
16	Bevacizumab: Analysis of clinical benefit in females across trials in colorectal cancer and non-small cell lung cancer 2007 ·Journal of Clinical Oncology ·David A. Ramies, Alan Sandler, Robert J. Gray, Bruce J. Giantonio, Julie R. Brahmer, Bruce Lyons, Joan H. Schiller	2
17	Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib breakdown → 2005 ·Journal of Clinical Oncology ·David A. Eberhard, Bruce E. Johnson, Lukas C. Amler, Audrey D. Goddard, Sherry Heldens, Roy S. Herbst, William L. Ince, Pasi A. Jänne, Thomas Januario, David H. Johnson, Pam Klein, Vincent A. Miller, (unknown), David A. Ramies, Dragan Sebisanovic, Jeremy Stinson, (unknown), Somasekar Seshagiri, Kenneth J. Hillan	1200
18	Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer 2005 ·Journal of Clinical Oncology ·Roy S. Herbst, David H. Johnson, Eric D. Mininberg, David P. Carbone, (unknown), Edward S. Kim, George Blumenschein, J. Jack Lee, Diane D. Liu, Mylene T. Truong, Waun Ki Hong, Hai T. Tran, Anne S. Tsao, Dong Xie, David A. Ramies, R. Mass, Somasekar Seshagiri, David A. Eberhard, Sean K. Kelley, Alan Sandler	452
19	Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774) 2004 ·Clinical Cancer Research ·Wells A. Messersmith, Daniel A. Laheru, Neil Senzer, Ross C. Donehower, (unknown), Theresa Rogers, Sean K. Kelley, David A. Ramies, Bert L. Lum, Manuel Hidalgo	68
20	Pathogen Inactivation of Plasma Using S-59 and UVA Light Is Efficacious and Well Tolerated in Liver Transplant Surgery - The STEP AC Trial 2002 ·Anesthesiology ·Randolph H. Steadman, Douglas P. Blackall, Lawrence D. Petz, Paul D. Mintz, David A. Ramies	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact